Drug profile · INN
idoxuridine
STOXIL
idoxuridine (STOXIL) is a dna inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — idoxuridine
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 3
- Programs
- 1
- Data quality
- 0.84
Quick answer
idoxuridine (STOXIL) is a dna inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10745352
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
granted -
US 10730834
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
granted -
US 9809539
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
granted
Frequently asked questions
What is idoxuridine?
idoxuridine (STOXIL) is a dna inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for idoxuridine?
STOXIL is a marketed brand name for idoxuridine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of idoxuridine?
idoxuridine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.